Increasing number of clinical pipeline studies is expected to boost the Influenza Therapeutics Market growth during the forecast period. For instance, in January 2018, Romark Laboratories L.C. initiated the phase 3 clinical trial for Nitazoxanide to evaluate its efficacy and safety in the treatment of uncomplicated influenza. Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral drug, used in the treatment of intestinal parasitic infections caused by Cryptosporidium parvam and Giardia lamblia. This study is expected to be completed in April 2019.

Influenza is a condition that causes contagious illness. It is characterized by sudden onset of fever, headache, sore throat, non-productive cough, and rhinitis. Usually infection lasts for about a week. Over the course of a flu season, different types and subtypes of influenza can cause illness in humans. There are four types of influenza virus such as A, B, C, and D. Influenza A and B virus causes most of the illness in humans. Prolonged influenza infections can cause severe complications such as pneumonia, bronchitis, acute respiratory distress, secondary bacterial infections, and cardiovascular complications. To control the illness caused by influenza virus, influenza antiviral prescription drugs can be used.

Influenza Therapeutics Market: Drivers

New drug approvals for the treatment of influenza is expected to drive the influenza therapeutics market growth. For instance, in October 2018, Roche announced that the U.S. Food and Drug Administration (FDA) approved Xofluza (TM) (baloxavir marboxil) for the treatment of acute, uncomplicated influenza or flu, in people 12 years of age and older.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2443

Moreover, in November 2018, Henry M. Jackson Foundation for the Advancement of Military Medicine, initiated phase 4 clinical trial study for egg-based influenza vaccines to study the realistic evaluation of influenza vaccine effectiveness in active duty members, military retirees, and other Department of Defense (DOD) beneficiaries.

Furthermore, rising initiatives by various sponsors to conduct phase 1 clinical trial to study the safety parameter of anti-influenza drugs is expected to drive the market growth. For instance, in October 2018, Emory University started phase 1 clinical trial for seasonal influenza vaccine. The study has been designed to evaluate the impact of imprinting and repeated influenza vaccination on adaptive immunity, transcriptomics, and metabolomics. The study is expected to be completed in July 2020.

Influenza Therapeutics Market: Restraints

Influenza vaccines have several limitations including relatively long production times, limited vaccine capacity, moderate efficacy in certain people, and lack of cross-reactivity, which is projected to restrain growth of the influenza therapeutic market during the forecast period. Moreover, increasing concerns among people about the side effects of vaccines hamper growth of the influenza therapeutic market. For instance, in October 2018, according to the National Opinion Research Centre (NORC) at the University of Chicago survey, around 43% of the adults were vaccinated and 14% plans to receive the flu shot. However, around 41% of the American people reported that they are not vaccinated and do not intend to get vaccinated, as adults were most likely to cite concerns about side effects of the vaccine.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/influenza-therapeutics-market-2443

Influenza Therapeutics Market: Regional Analysis

On the basis of region, the global influenza therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Asia Pacific is also expected to witness significant growth in the influenza therapeutics market, owing to increasing initiatives by the Asia-Pacific Alliance for the Control of Influenza (APACI), to reduce the burden of influenza by enhancing control measures and boosting pandemic preparedness in the region, through the provision of educational information and activities.

Europe have also gained significant position in the market, owing to increasing initiatives by European Medical Association (EMA) during an influenza pandemic season leading to continuous monitoring of safety of centrally authorized pandemic influenza vaccines and antiviral medicines, and fast-track review of data for the authorization of pandemic influenza vaccines for use in all EU Member States. Also, increasing number of public awareness programs for the prevention and diagnosis of influenza resulted in significant growth of the influenza therapeutics market in this region.

Key players operating in the global influenza therapeutic market include Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd., BiondVax Pharmaceuticals Ltd., Atriva Therapeutics Gmbh, Texas Medical Center, Life Science Austria (LISA), GE Healthcare Life Sciences, Sanofi Pasteur SA and Mylan, Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2443

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737